Drug Trial Radar · NCT00094653
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Last checked: Nov 20, 2026Latest source record: Jul 11, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,783
Actual
Start
Sep 2004
Primary completion
Aug 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Oct 22, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and efficacy of MDX-010 (ipilimumab, BMS-734016) (anti-CTLA4) in combination with MDX-1379 (gp100, BMS-734019) in patients with previously treated, unresectable Stage III or IV melanoma. Survival time will be evaluated, as well as patient responses and time to disease progression. Eligible patients are those who in response to a single regimen containing interleukin-2 (IL-2), dacarbazine, and/or temozolomide, have 1) relapsed following an objective response (partial response/complete response \[PR/CR\]); 2) failed to demonstrate an objective response (PR/CR); or 3) could not tolerate such a regimen due to unacceptable toxicity. Patients will be randomized into one of three groups, and will receive one of the following treatments: MDX-010 alone, MDX-1379 alone, or MDX-010 in combination with MDX-1379.
Conditions
- Melanoma
- Metastases
Interventions
MDX-010 (anti-CTLA4) monoclonal antibodyDrug
3mg/kg (intravenous \[iv\] infusion over 90 minutes), every 3 weeks for 4 doses
MDX-1379 (gp100) Melanoma Peptide VaccineBiological
2mL (2 subcutaneous injections of 2 mL each, 1 to each thigh), every 3 weeks for 4 doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine AloneTime frame: From randomization until the end of the study, which was defined as the time at which 481 deaths were observed (264 weeks)
Locations
209 sites in 13 countries. Site status is shown where the registry gives one.
Arizona Cancer Center
Tucson, Arizona
University Medical Center
Tucson, Arizona
City of Hope National Medical Center
Duarte, California
San Diego Cancer Center
Encinitas, California
La Jolla Hematology and Oncology Medical Group
La Jolla, California
Scripps Cancer Center
La Jolla, California
Moores UCSD Cancer Center
La Jolla, California
Pacific Shores Medical Group
Long Beach, California
Cancer Institute Medical Group, Inc
Los Angeles, California
The Angeles Clinic and Research Institute
Los Angeles, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California
North County Oncology Medical Clinical, Inc.
Oceanside, California
City of Hope Medical Group
Pasadena, California
University of California, San Diego
San Diego, California
St. Mary's Medical Center - Northern California Melanoma Center
San Francisco, California
Cancer Institute Medical Group, Inc
Santa Monica, California
San Diego Cancer Center
Vista, California
Anschutz Cancer Pavilion
Aurora, Colorado
Rocky Mountain Cancer Centers
Aurora, Colorado
University of Colorado Health Sciences Center
Aurora, Colorado
Rocky Mountain Cancer Centers
Boulder, Colorado
Rocky Mountain Cancer Centers
Colorado Springs, Colorado
Rocky Mountain Cancer Centers
Denver, Colorado
University of Colorado Hospital
Denver, Colorado
Rocky Mountain Cancer Centers
Lakewood, Colorado
Rocky Mountain Cancer Centers
Littleton, Colorado
Rocky Mountain Cancer Centers
Lone Tree, Colorado
Rocky Mountain Cancer Centers
Longmont, Colorado
Yale University School of Medicine - Oncology Outpatient Clinic
New Haven, Connecticut
Mount Sinai Comprehensive Cancer Center at Aventura
Aventura, Florida
Memorial Regional Cancer Center
Hollywood, Florida
Shands Jacksonville
Jacksonville, Florida
University of Florida/Jacksonville Faculty Clinic
Jacksonville, Florida
Jackson Memorial Hospital & Clinics
Miami, Florida
University of Miami Hospital & Clinics
Miami, Florida
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
Mount Sinai Medical Center
Miami Beach, Florida
M.D. Anderson Cancer Center Orlando
Orlando, Florida
Palm Beach Cancer Institute
Palm Beach Gardens, Florida
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida
Showing 40 of 209 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.